CAMBRIDGE, Mass. — Vyome Holdings said it has published positive preclinical data supporting the efficacy and safety of VT-1908 as a potential treatment for uveitis, positioning the program as a possible alternative to topical steroids in a large and underserved market.
The company announced that the data were published in the peer-reviewed Journal of Ophthalmic Inflammation and Infection, validating VT-1908’s performance in a uveitis preclinical model. Uveitis, an immune-driven inflammation of the eye, accounts for an estimated 10 to 15 percent of blindness cases in the developed world and is linked to roughly 30,000 new cases of legal blindness each year in the United States. The condition represents an estimated $3 billion market opportunity by 2032.
According to the publication, topical administration of VT-1908 achieved therapeutic drug concentrations in the eye without irritation or signs of toxicity. Treated eyes showed a statistically significant reduction in uveitis scores and lymphocyte counts in the anterior chamber compared with vehicle control. The study found VT-1908 to be as effective as topical prednisone in the preclinical model.
“There remains a significant unmet need for safe and effective topically administered therapies to replace topical steroid use in the treatment of ocular inflammation. While steroids are widely used, they are associated with well-documented complications. The fact that VT-1908 was as effective as a steroid in the uveitis preclinical model and shows a very good safety profile supports its potential as an effective alternative to steroids in the eye,” said Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and co-founder of Vyome.
Vyome said it plans to leverage the India innovation corridor to advance VT-1908 into clinical development in a cost-efficient manner to generate initial human clinical data.
“The publication of this paper in the peer-reviewed Springer-Nature journal underscores the scientific rigor underlying Vyome’s approach to addressing inflammation in the eye. The broader addressable global market to treat inflammation in the eye is expected to exceed $20 billion by 2030,” said Venkat Nelabhotla, CEO of Vyome. “Based on our pre-clinical findings, we intend to leverage the India innovation corridor to advance VT-1908 into clinical development in a very capital-efficient manner, to generate human clinical data that could result in a significant value inflection.”
The company said there is no change to its capital deployment plans and that it remains focused on its lead program, VT-1953, which is in a Phase 3 study for the treatment of malodor of malignant fungating wounds. Vyome estimates the U.S. addressable market opportunity for VT-1953 at approximately $2.2 billion.
